G1 Therapeutics Posted 242.59% Returns Year-to-Date

G1 Therapeutics stock movements

G1 Therapeutics (GTHX), a clinical-stage company, has risen 242.59% YTD (year-to-date), mainly due to its three important oncology research programs achieving major milestones. It was led by its most advanced clinical program for investigational first-in-class, short-acting, intravenously-administered cyclin-dependent kinase 4/6 (or CDK 4/6) inhibitor trilaciclib in the first half of 2018.

The consensus recommendation for G1 Therapeutics over the next 12 months is a “buy.” Of the six analysts covering the company in September, two have recommended a “strong buy,” and four have recommended a “buy.”

Wall Street analysts have projected a 12-month consensus target price for G1 Therapeutics of $67, which would be a decline of 1.43% over its closing price on September 13.

G1 Therapeutics Posted 242.59% Returns Year-to-DateThe above chart highlights the key milestone events that could impact G1 Therapeutics stock in the future.

Growth drivers

G1 Therapeutics is targeting the myelopreservation market, worth more than $7 billion, with trilaciclib, which is currently being evaluated in multiple Phase 2 trials. The drug is being tested as a backbone therapy in combination regimens in first-line, second-line, and third-line small cell lung cancer, as well as in metastatic triple-negative breast cancers. All these indications are hard to treat, and the company thus expects to benefit from significant unmet demand in those areas.

It’s also targeting the oral CDK4/6 market, worth more than $20 billion, with investigational CDK4/6 inhibitor lerociclib. G1 It’s also targeting the selective estrogen receptor degrader (or SERD) market in the ER+ (estrogen-receptor-positive) breast cancer segment, which is worth more than $1 billion.

As of June 30, G1 Therapeutics had $188.2 million in cash on its balance sheet.

In the next part, we’ll look at the growth trends for Sarepta Therapeutics.